Open Access Open Access  Restricted Access Subscription or Fee Access

Role of Bioinformatics in Cancer Diagnostic Advancements

R. Singh


Cancer is one of the most common diseases responsible for death these days. It is a disease determined by several genetic and epigenetic alterations. It is a complex disease occurring in multiple organs per system, multiple systems per organ, or both, in the body. Cancer is characterized as uncontrolled growth of cells due to failure of cell cycle checkpoints. Despite various advancements in cancer treatment it is not possible treat cancer with 100% success rates. The biggest challenge faced by researchers is that disease varies drastically from patient to patient. With increasing evidence that the interaction and network between genes and proteins play an important role in investigation of cancer molecular mechanisms, it is necessary and important to introduce a new concept of Systems Clinical Medicine into cancer research, to integrate systems biology, clinical science, omics-based technology, bioinformatics and computational science to improve diagnosis, therapies and prognosis of diseases. Cancer bioinformatics deals with the organization and analysis of the data so that important trends and patterns can be identified – the ultimate goal being the discovery of new therapeutic and/or diagnostic protocols for cancer.

Full Text:



X.D. Wang, L. Liotta L. Clinical bioinformatics: a new emerging science, J Clin Bioinform. 2011; 1(1): 1p. 10.1186/2043-9113-1-1.

M.E. Holford, J.P. McCusker, K.H. Cheung, M. Krauthammer. A semantic web framework to integrate cancer omics data with biological knowledge, BMC Bioinform. 2012; 13(Suppl 1): S10p. 10.1186/1471-2105-13-S10-S10.

M.T.W. Ebbert, R.R.L. Bastien, K.M. Boucher, M. Martín, E. Carrasco, R. Caballero, I.J. Stijleman, P.S. Bernard, J.C. Facelli. Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans, J Clin Bioinforma. 2011; 1: 37p. 10.1186/2043-9113-1-37.

C. Laczny, P. Leidinger, J. Haas, N. Ludwig, C. Backes, A. Gerasch, M. Kaufmann, B. Vogel, H.A. Katus, B. Meder, et al. miRTrail – a comprehensive webserver for analyzing gene and miRNA patterns to enhance the understanding of regulatory mechanisms in diseases, BMC Bioinform. 2012; 13(1): 36p. 10.1186/1471-2105-13-36.

Y. Kimori. Mathematical morphology-based approach to the enhancement of morphological features in medical images. J Clin Bioinforma. 2011; 1: 33p. 10.1186/2043-9113-1-33.

V. Haustein, U. Schumacher. A dynamic model for tumour growth and metastasis formation, J Clin Bioinforma. 2012.

S. von der Heyde, T. Beissbarth. A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancer, BMC Med. 2012.

X.D. Wang. Role of clinical bioinformatics in the development of network-based biomarkers, J Clin Bioinforma. 2011; 1: 28p. 10.1186/2043-9113-1-28.

D.J. Wu, D. Zhu, M. Xu, R.M. Rong, Q.Y. Tang, X.D. Wang, T.Y. Zhu. Analysis of transcriptional factors and regulation networks in patients with acute renal allograft rejection, J Proteome Res. 2011; 10(1): 175–81p. 10.1021/pr100473w.

H. Chen, Z.J. Song, M.J. Qian, C.X. Bai, X.D. Wang. Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: a preliminary study, J Cell Mol Med. 2011; Aug 25. doi: 10.1111/j.1582–4934.2011.01416.x.

Y. Cun, H. Fröhlich. Prognostic gene signatures for patient stratification in breast cancer – accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions, BMC Bioinform. 2012. (MS: 1321151249583179 in pre-accept).

H. Chen, Y. Wang, C. Bai, X.D. Wang. Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation, J Proteomics. 2012, 10p.

L. Hood, S.H. Predictive, personalized, preventive, participatory (P4) cancer medicine, Nat Rev Clin Oncol. 2011; 8: 184–7p. 10.1038/nrclinonc.2010.227.

L. Hood, J.R. Heath, M.E. Phelps, B. Lin. Systems biology and new technologies enable predictive and preventative medicine, Science. 2004; 306(5696): 640–3p. 10.1126/science.1104635.

Q. Tian, N.D. Price, L. Hood. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine, J Intern Med. 2012; 271(2): 111–21p. 10.1111/j.1365-2796.2011.02498.x.

X. Ren, Y. Wang, J. Wang, X.S. Zhang. A unified computational model for revealing and predicting subtle subtypes of cancers, BMC Bioinform. 2012.

A. González-Beltrán, B. Tagger, A. Finkelstein. Federated ontology-based queries over cancer data, BMC Bioinform. 2012; 13(Suppl 1): S9p. 10.1186/1471-2105-13-S11-S9.

E.T. Sawey, M. Chanrion, C. Cai, G. Wu, J. Zhang, L. Zender, A. Zhao, R.W. Busuttil, H. Yee, L. Stein, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening, Cancer Cell. 2011; 19(3): 347–58p. 10.1016/j.ccr.2011.01.040.

S. Nagl (ed). Cancer Bioinformatics; From Therapy Design to Treatment. Vol. 30, Publisher: John Wiley & Sons; 2006, 287p.


  • There are currently no refbacks.